LGALS1 and Patent ductus arteriosus: Increased levels of CA19-9 have been also reported in up to 50% of diabetic patients [61] and in PDA patients with diabetes [62], suggesting additional advantages of using Gal-1 as a PDA biomarker in conjunction with CA19-9 rather than CA19-9 alone.